ExonHit licenses Merck rights to RNA splicing microarray patent

Download PDF Copy

Editorial Checklist

Reviewed

Sep 11 2006

ExonHit Therapeutics S.A., a drug and diagnostic discovery company, has announced that Merck & Co., Inc. has been granted a non-exclusive license to rights for research only under Patent US 6,881,571.

It is not anticipated that the revenues received by ExonHit from Merck under this agreement will exceed US$150,000 per year.

Patent US 6,881,571, entitled "Qualitative Differential Screening", was granted on April 19, 2005 and has claims directed to microarrays optimized for the monitoring of RNA splicing events.

Source:

http://www.exonhit.com

Posted in: Medical Patent News

Comments (0)

Download PDF Copy

Suggested Reading

Low vitamin D levels damage erectile health via superoxide surge, study finds

Low vitamin D levels damage erectile health via superoxide surge, study finds

Gut bacteria and metabolites reveal depression-linked patterns in older adults

Gut bacteria and metabolites reveal depression-linked patterns in older adults

Cheese isn't just food—it’s a microbiome booster, study confirms

Cheese isn't just food—it’s a microbiome booster, study confirms

Boost your transfection success with these proven expert tips

Boost your transfection success with these proven expert tips

Scientists uncover how herpes virus fuels Alzheimer’s disease

Scientists uncover how herpes virus fuels Alzheimer’s disease

Scientists pinpoint metabolic failure as the cause of muscle loss in aging

Scientists pinpoint metabolic failure as the cause of muscle loss in aging

Hedonic eating fades with obesity—but neurotensin helps bring it back

Hedonic eating fades with obesity—but neurotensin helps bring it back

Blood test detects Parkinson’s years before symptoms appear using RNA markers

Blood test detects Parkinson’s years before symptoms appear using RNA markers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Oropouche virus goes global: Study exposes new risks from viral reassortment